You have shown yourself on hundreds of CYP posts to be vitriolic...

You have shown yourself on hundreds of CYP posts to be vitriolic to posters, devoid of any real understanding of IPSC's, their regulatory advancements (and similarly very little comprehension of MSB's long standing FDA woes on threads therein too), CYP's trial progression, cash uses, potential commercial or partnership likelihoods or indeed CYP's timelines and pathways - despite their very clear explanations.

You cannot even grasp the the fundamentals of finance. CYP traded over 2 million shares today. Versus its shares on issue a near 1% daily turnover in shares is adequate liquidity or "coin" as you ignorantly put it, for holders to trade positions within, versus its relatively small mkt cap - that would be shares on issue x traded price Gavsey. Perhaps grasp simply things like average daily volume vs shares outstanding, let alone attempting to talk about safety of IPSC technology. Cynata and dozens of other IPSC companies have demonstrated the safety of IPSC treatments in phase I/II trials globally. You do grasp that first and foremost phase I trials are concerned primarily with establishing safety and dose ranges usually in about 20-50 healthy volunteers? There's been rather a lot of them globally which , yawn, as I only explained yesterday, is why the FDA (and other regulatory authorities) have been happy to clear investigational NDA's for a multitude of IPSC treatments.

Do try and read a bit on a subject before typing one's errant simple thoughts on it Gavsey, or at least run it by your more medically informed siblings, wife and children first (again your past revelations).